Called cagrisema, the drug reduced, on average, 20.4% of patients’ body weight, surpassing Ozempic results
The search for medicines for the weight loss It has increased considerably in recent months. And now patients with balance problems will have new alternatives. They are two experimental drugs, including one of oral use.
The products were developed by Novo Nordisk, the same pharmacist responsible for the creation of the famous Ozempic. The idea is not only to provide medicines against obesity, but also give options to avoid getting fat again.
Tests indicated greater weight loss
One of the new medicines is Cagrisema, considered to be the successor of Ozempic. The main difference of the product is that it is not only targeted by the GLP-1 receiver, through Semaglutida, but also has the presence of an amiline analog (cagrilintide). This combination affects the signs of brain satiety and decreases appetite.
After 68 weeks of testing, 3,417 overweight or obese participants lost an average of 20.4% of body weight from the use of the drug. This exceeds the results of available drugs today, which allow an average loss of 15% of body weight.
In addition, cagrisema performed slightly better in terms of loss of fat versus muscle loss. The goal of Novo Nordisk is to launch the product in its subcutaneous injectable version and with application once a week in 2026. The information is from the portal New Atlas.
read more
Oral use medicine is also being developed
- The pharmacist also released the results of two tests involving the experimental drug for amicrect weight loss.
- The differential of this product is the possibility of oral use.
- After 36 weeks of analysis with 125 adults aged 18 to 55, the drug was effective and advanced to the last step before a possible release.
- Unlike the semaglutidal-crackling combination, this is a unique molecule that activates amiline and LPG-1 receptors.
- Overall, a 20 mg dose resulted in an average weight loss of 13.1% over a period of 36 weeks.
- The problem is that 70% of participants experienced mild or moderate gastrointestinal problems, including nausea or vomiting.
- The next step is to test as variations in the concentration of substances can act in the body.
- Therefore, there is no forecast of launching the medicine.
Collaboration for the digital look
Alessandro Di Lorenzo has a degree in Journalism from the Federal University of Rio Grande do Sul (UFRGS) and has been working in the area since 2014. He worked on BandNews FM newsrooms in Porto Alegre and São Paulo.
